Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4800-4806

  Fingleton, Barbara ^a   Carter, Kathy J ^a   Matrisian, Lynn M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; FAS LIGAND;

ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL INFILTRATION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; INTESTINE POLYP; INTESTINE TUMOR; LYMPHOCYTE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADENOMA; ANIMALS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; GENES, APC; HUMANS; INFLAMMATION; INTESTINAL NEOPLASMS; INTESTINAL POLYPS; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUTATION;

EID: 34250344092     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4473     Document Type: Article

References (51)

1. Tanaka M, Itai T, Adachi M, Nagata S. Down regulation of Fas ligand by shedding. Nat Med 1998;4:31-6.
2. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999;9: 1441-7.
3. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 2002;408:155-61.
4. Ju S-T, Panka DJ, Cul H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
5. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133:335-43.
6. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004;16:139-44.
7. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76.
8. Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984;59:1-20.
9. Lynch DH, Watson ML, Alderson MR, et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994;1:131-6.
10. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46-52.
11. Igney FH, Behrens CK, Krammer PH. Tumor counterattack - concept and reality. Eur J Immunol 2000;30:725-31.
12. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo1/CD95) ligand: implications for tumor immune escape. Science 1996;274:1363-6.
13. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat Med 1996;2:1361-6.
14. Walker PR, Saas P, Dietrich P-Y. Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol 1998;10:564-72.
15. Ottonello L, Tortolina G, Amelotti M, Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999; 162:360-1.
16. Seino K-I, Iwabuchi K, Kayagaki N, et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998;161:4484-8.
17. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997;3:165-70.
18. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997;94:13862-7.
19. Moser AR, Luongo C, Gould KA, et al. ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 1995;31A:1061-4.
20. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256: 668-70.
21. Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A 2002;99:1521-6.
22. Kilpatrick L, McCawley L, Nachiappan V, et al. α-1-Antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes. J Immunol 1992;149:3059-65.
23. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-78.
24. Belluco C, Esposito G, Bertorelle R, et al. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 2002;28:120-5.
25. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998;4:63-8.
26. Luongo C, Moser AR, Gledhill S, Dove WF. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res 1994;54:5947-52.
27. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001;3:459-68.
28. Sayers TJ, Brooks AD, Seki N, et al. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas. J Leukoc Biol 2000;68:81-6.
29. Zhang HG, Fleck M, Kern ER, et al. Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest 2000;105:813-21.
30. Okayasu I, Hatekeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
31. O'Connell J, Bennett MW, O'Sullivan GC, et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 1998;186:240-6.
32. O'Connell J, Bennett MW, O'Sullivan GC, et al. Expression of Fas (CD95/Apo-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol 1999;6:457-63.
33. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184:1075-82.
34. Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000;6: 493-5.
35. Igney FH, Behrens CK, Krammer PH. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int J Cancer 2004;113:78-87.
36. Ryan AE, Shanahan F, O'Connell J, Houston AM. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005;65: 9817-23.
37. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
38. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
39. Aoki K, Kurooka M, Chen J-J, et al. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol 2001;2: 333-7.
40. Chen J-J, Sun Y, Nabel GJ. Regulation for the proinflammatory effects of Fas ligand (CD95L). Science 1998;282:1714-7.
41. Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 2001;167:6217-24.
42. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression in inflammation and tumor cell survival. J Exp Med 2000;191:1209-19.
43. Seino K, Ogino T, Fukunaga K, et al. Attempts to reveal the mechanism of CD95-ligand-mediated inflammation. Transplant Proc 1999;31:1942-3.
44. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997;94:1402-7.
45. Fingleton B, Powell WC, Crawford HC, Couchman JR, Matrisian LM. A rat monoclonal antibody that recognizes pro- and active MMP-7 indicates polarized expression in vivo. Hybridoma 2007;26:22-7.
46. Kang S-M, Braat D, Schneider DB, et al. A noncleavable mutant version of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 2000;69:1813-7.
47. Beck PL, Wong J, and Muruve D. The regulation of Fas and Fas ligand alters the severity of a murine model of colitis. Gastroenterology 2002;122:A269-270.
48. Sayani FA, Keenan CM, Van Sickle MD, et al. The expression and role of Fas ligand in intestinal inflammation. Neurogastroenterol Motil 2004;16:61-74.
49. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
50. Josephy PD, Coomber BL. The 1996 Veylien Henderson Award of the Society of Toxicology of Canada. Current concepts: neutrophils and the activation of carcinogens in the breast and other organs. Can J Physiol Pharmacol 1998;76:693-700.
51. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.